Referenser
1. Johnson M, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006;20:711-18.
2. Johnson M, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005;19:685-94.
3. Zaccarelli M, et al. Lipodystrophy is associated with low rate of treatment failure in HIV-positive patients switched to boosted atazanavir (ATV/r). The 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro 2005. TuPe 2.2B13.
4. Guillemi S, et al. Changes in lipid profile upon switch ing from a lopinavir/RTV (LPV/R) to atazanavir /RTV (ATZ/R)-based HAART. Abstract presented at IAC, Toronto, Canada, 2006. WEPE0156.
5. Moreno S, et al. Once-daily salvage regimens for multiexperienced HIV-infected patients. Data from BMS study 900: atazanavir (ATV) early access in Spain. Abstract presented at IAC, Toronto, Canada, 2006. WePe12.9CO1.
6. Piketty C, et al. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial. Antiviral Therapy 2006;11: 213-21.
7. Trevino S, et al. An open label study to assess the safety and efficacy of switching from a protease inhibitor (PI) to a boosted atazanavir (ATV/r) regimen Abstract presented at IAC, Toronto, Canada, 2006. CDB0511.
8. Pellegrin I, et al. Virological response to atazanavir/ritonavir-based regimens: resistance-mutations score and pharmacokinetics (Reyaphar study).46th Interscience Conference on Antimicrobial Agents and Chemotherapy H-1058.
9. Pellegrin I, et al. Switch to atazanavir/ritonavir based HAART in patients with virolgic Success on HAART: Impact of Proviral DNA-HIV Genotype and Pharmacokinetics on Sustained response at M6 (Reyaphar Study). ICACC 2005. H-524.
10. Perez-Elias MJ, et al. Effect of ritonavir-boosted atazanavir (ATV/r) in experienced HIV-infected patients regarding hepatitis B/C status. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil, 2005. Poster #TuPe1.1c25.
11. Rivero A, et al. Switching from boosted protease inhibitors (PI/r) to boosted atazanavir (ATZ/r) in HIV patients with undetectable viral load. Abstract presented at EACS, Dublin, Ireland, 2005. Abstract PE7.5/10.
12. Vora S, et al. Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. Abstract presented at EACS, Dublin, Ireland, 2005. Abstract PS6/3.
13. Johnson M, et al. Long-term efficacy and durability of atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) versus lopinavir/ritonavir (LPV/RTV) in HIV-infected patients with multiple virologic failures: 96-week results from a randomized, open-label trial, BMS A1424045. 7th ICDTH, Glasgow, United Kingdom, 2004. Poster #PL14.14.
14. De Wit S, Poll B, Nescoi C, Clumeck N. Atazanavir has a better impact on lipid profiles than fosamprenavir and lopinavir in patients matched for baseline triglycerides and cholesterol. Abstract P127. 8th International Congress on Drug Therapy in HIV Infection. November 12-16, 2006, Glasgow.
15. Martinez E, et al. Effects of switching to ritonavir-boosted atazanavir (ATV) on hyperlipidaemia of HIV-infected patients receiving antiretroviral therapy. 12th Conference on Retroviruses and Opportunistic Infections, Boston, United States, 2005. Poster K-184.
16. El Benjjani, et al. Effect of starting atazanavir (ATV)-based therapy on lipids and bilirubin. Abstract presented at IDSA, San Francisco, United States, 2005. Abstract 810.
17. Holmes PM, et al. Atazanavir: 12 months of clinical experience in 241 individuals. Abstract presented at EACS, Dublin, Ireland, 2005. Abstract PE7.9/9.